Zimmer Biomet posts second-quarter results

Zimmer Biomet reported second-quarter 2026 results on August 5, posting $2.177 billion in net sales and saying it received an FDA 510(k) clearance during the quarter. The Warsaw, Indiana-based orthopedic device maker said sales rose 4.8% from a year earlier, or 4.7% on a constant-currency basis. Diluted earnings per share were $1.03, up 33.8%, while adjusted diluted earnings per share were unchanged at $2.07. The company also updated its full-year 2026 financial guidance and used the quarter to highlight progress in what it calls MedTech, including its procedural, robotic and digital businesses. Zimmer Biomet said operating cash flow was $447.9 million in the quarter and free cash flow was $308.3 million. ### How strong were the quarter’s headline numbers? (biospace.com) Second-quarter net sales of $2.177 billion compared with $2.077 billion a year earlier, according to Zimmer Biomet’s earnings release and SEC filing. Net earnings were $198.3 million, or $399.6 million on an adjusted basis. The company said organic constant-currency sales growth was 4.0%. (biospace.com) Adjusted earnings per share of $2.07 matched the prior-year period, even as reported diluted earnings per share rose from the year-earlier quarter. Zimmer Biomet said the results covered the quarter ended June 30, 2026. ### What did Zimmer Biomet say about the FDA clearance? Zimmer Biomet said in its second-quarter release that it received an FDA 510(k) clearance during the quarter, adding a regulatory milestone to its commercial update. (biospace.com) The company’s recent FDA-cleared product announcements have centered on its ROSA robotic platform, including ROSA Knee with OptimiZe, which it said received 510(k) clearance in November 2025 for an enhanced knee robotic workflow. The August 5 earnings materials available through Zimmer Biomet’s investor site list the second-quarter results release, but the company’s summary pages do not spell out the cleared product in the index text. Zimmer Biomet separately said earlier this year that its ROSA Shoulder System had become the first robotic assistant cleared for shoulder replacement surgery. (biospace.com) ### Where is the company putting emphasis inside the business? Zimmer Biomet used the quarter to point investors to procedural technology, a category that includes robotics, navigation and connected operating-room tools. On its investor site, the company describes itself as a medical technology company focused on musculoskeletal healthcare and says its portfolio includes integrated digital and robotic technologies. (investor.zimmerbiomet.com) Recent company releases show that emphasis extending beyond implants. In 2025, Zimmer Biomet agreed to acquire Monogram Technologies to broaden its robotics suite, and in 2026 it continued presenting new products and technology updates through its investor communications. ### Did the company change its outlook? (investor.zimmerbiomet.com) Zimmer Biomet said it updated full-year 2026 financial guidance in the August 5 release. Market summaries based on the earnings report said the company raised its expected revenue growth range and lifted adjusted earnings-per-share guidance to $8.47 to $8.59. The company had previously told investors on July 13 that it would release second-quarter results on August 5 at 6:30 a.m. (investor.zimmerbiomet.com) Eastern time and hold its conference call at 8:30 a.m. that day. ### Where can investors find the next set of details? Zimmer Biomet’s August 5 earnings release is posted on its investor relations site, and the company filed the results with the U.S. (biospace.com) Securities and Exchange Commission on Form 8-K the same day. The investor site also lists archived quarterly results and news releases for 2026. (investor.zimmerbiomet.com) The next formal financial update is likely to come with Zimmer Biomet’s third-quarter 2026 results, which would follow the company’s usual quarterly reporting cycle through its investor relations page and SEC filings. That page also carries webcast information and future event postings. (investor.zimmerbiomet.com) (sec.gov)